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Background—Electrical  heterogeneity  of  the  right  ventricular  outflow  tract  (RVOT)  is  regarded  as  one  of  the  main 
electrophysiological substrates for Brugada syndrome. Recently quinidine has shown efficacy in patients with Brugada 
syndrome due to its ability to inhibit potassium current especially 4-aminopyridine–sensitive, non-Ca2+-dependent transient 
outward potassium current (Ito). However, much less is known on how extent quinidine in clinical therapeutic concentration 
range can inhibit this kind of electrical heterogeneity of RVOT Ito.
Methods and Results—Single RVOT free wall epicardial (Epi) cell, midmyocardial (M) cell and endocarcial (Endo) cells were 
used for whole-cell voltage clamping and Ito was recorded at 37°C, 0.2 Hz depolarization pulse. Evident Ito tranmural 
heterogeneity existed in RVOT free wall. Under the condition of baseline, of 10 µM quinidine perfusion 5 minutes (mins), 
and of 10 µM quinidine perfusion 7–10 mins, from 0 mV to 70 mV the whole transmural average Ito values of RVOT free 
wall were 10.2 pA/pF, 5.5 pA/pF and 3.5 pA/pF, respectively (between groups, P<0.01). The inhibitory percentage of 10 
µM quinidine at 5 mins and 7–10 mins steady-state level on the the whole Ito transmural heterogeneity of RVOT free wall 
were 46.3%±6% and 66.5%±11%, respectively.
Conclusions—There exists a robust Ito transmural electrical heterogeneity in RVOT free wall and quinidine in clinical 
therapeutic concentration can depress this kind of heterogeneity effectively.
Keywords: arrhythmia, Brugada syndrome, idiopathic ventricular fibrillation, quinidine,  
transient outward potassium current
INTRODuCTION
It’s  estimated  every  year  there  are  200,000–400,000  persons 
suffered from sudden cardiac death (SCD) in the USA only.1 
SCD is the leading cause for middle-aged death and it forms 
a big challenge to public health all over the world.1 SCD most 
commonly  occurs  as  a  consequence  of  acute  myocardial 
ischemia or develops with identifiable substrate such as scar 
because  of  previous  myocardial  infarction,  cardiomyopathy, 
or  hypertrophy.  Despite  extensive  noninvasive  and  invasive 
evaluation,  SCD  remains  unexplained  without  evidence  of 
structural heart disease in about 10% of individuals surviving 
SCD. It is now recognized that inherited electrophysiological 
abnormalities,  termed  primary  electrical  diseases,  are  the 
common underlying cause of these unexplained cardiac arrests. 
These  conditions  include  Wolff-Parkinson  White  syndrome, 
long QT syndrome, Brugada syndrome and catecholaminergic 
polymorphic  ventricular  tachycardia  (CPVT),  short  QT 
syndrome and idiopathic ventricular fibrillation (IVF).2 As a 
kind of ion channelopathy paradigms and monogenic mutant 
leading to SCD, Long QT syndrome, Brugada syndrome and 
short QT syndrome provide us with some important keys to 
understand  the  electrophysiological  mechanism  of  SCD.3–9 
Recently, more and more experimental studies have suggested 
that  Brugada  syndrome  and  some  IVFs  originate  from  the 
right ventricular outflow tract (RVOT), and regional transmural 
heterogeneity is one of the main electrophysiological substrates 
of malignant arrhythmias caused by Brugada syndrome, short 
QT syndrome and some IVFs.10–13
Prominent  4-aminopyridine–sensitive,  non-Ca2+-depen 
dent  transient  outward  potassium  current  (Ito)  of  right 
ventricular epicardial (Epi) cell and midmyocardial (M) cell is 
one of the most prominent and important manifestations of 
the right ventricular transmural electrical heterogeneity.7 The 
prominent  Ito  mediated  action  potential  notch  in  Epi  cells 
and M cells, but not that in endocardial (Endo) cells, create Quinidine Depresses the Ito Heterogeneity from RVOT
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transmural  voltage  gradients  and  thus  cause  ST-segment 
elevation. Right ventricular Ito is an important ionic basis for 
repolarization “spike and dome” morphology, phase 2 “all or 
none”  repolarization,  action  potential  plateau  heterogeneous 
loss  and  phase  2  reentry.  On  the  basis  of  phase  2  reentry, 
ventricular tachycardia (VT) or ventricular fibrillation (VF) can 
be precipitated easily by a short coupling extrasystole. This is one 
of the most important electrophysiological mechanisms which 
are responsible for SCD of Brugada syndrome and some IVF 
victims.7,12 Because the presence of a prominent Ito in the RVOT 
is regarded as an important link to the mechanism underlying 
the  Brugada  syndrome,  the  important  rational  approach  to 
therapy, regardless of the ionic or genetic basis for the disease, is 
to partially inhibit Ito.14–17 As a robust potassium current inhitor 
especially Ito inhibor, quinidine is effective in suppressing wedge 
arrhythmogenesis models of the Brugada syndrome.12 Clinically, 
although implantation of an automatic implantable cardioverter 
defibrillator (ICD) is the recommended first choice for most of 
the Brugada syndrome, short QT syndrome and IVF patients, 
antiarrhythmic therapy with quinidine aimed at rebalancing the 
currents activity during phase 1 of the right ventricular action 
potential is used to abort electrical storms, as an adjunct to 
device therapy, and as an alternative to device therapy when 
use  of  an  ICD  is  not  possible.14–17  Today,  more  and  more 
evidence has shown the excellent long-term reproducibility of 
the electrophysiological efficacy of quinidine in patients with 
Brugada syndrome, short QT syndrome and some IVFs.18–23
However,  limited  information  can  be  available  on  how 
effective of quinidine on restoring the Ito electrical homogeneity 
of  the  RVOT.  In  this  study,  we  examined  the  Ito  electrical 
heterogeneity of the RVOT free wall and the effect of clinical 
therapeutic concentration quinidine on this kind of Ito electrical 
heterogeneity.
MATERIAlS AND METHODS
Prepared solutions
The following solutions were prepared as previously described 
by  our  laboratory:24  Ca2+-free  buffer  solution  (in  mmol/L): 
NaCl 126, KCl 5.4, MgCl2 1.0, D-glucose 22, NaH2PO4 0.9, 
and HEPES 5 (pH adjusted to 7.35 with NaOH); cell storage 
solution: Ca2+-free buffer solution (see above) 200 ml, BSA 
0.5 g, 0.05 mmol/L CaCl2 1 ml; enzymatic solution: Ca2+-free 
buffer solution (see above) 200 ml, collagenase-II 50 mg (Sigma 
Co., USA), proteinase-XIV 20 mg (Sigma Co., USA), BSA 200 
mg, 0.05 mmol/l CaCl2 1 ml; pipette solution (in mmol/L): K2-
ASP 125, KCl 20, MgCl2 1.0, Mg-ATP 5.0, HEPES 5.0, and 
EGTA 10.0 (pH adjusted to 7.1–7.2 with KOH); extra cellular 
solution (in mmol/L): NaCl 132, KCl 4.0, CaCl2 2.0, MgSO4 
1.2, HEPES 20, and D-glucose 11.1 (pH adjusted to 7.40 with 
NaOH). CaCl2 was prepared from stock solutions just before 
use.
Isolating canine right ventricular outflow  
tract free wall cells
The methods and protocols used in canine were approved by 
Capital Medical University Animal Care and Use Committee 
and  conformed  to  the  Guide  for  the  Care  and  Use  of 
Laboratory Animals published by the U.S. National Institutes 
of Health (NIH Publication 85–23, revised 1985). Cells were 
prepared as previously described by our laboratory and Paul 
G. A. Volders’experience.24,25 Briefly, 15 mongrel dogs of either 
sex (about 18±4 kg each) were anesthetized with pentobarbital 
sodium  (30  mg/kg).  Their  hearts  were  excised  quickly  and 
placed into Ca2+-free buffer solution gassed with 95% O2-5% 
CO2. The right coronary artery branches, which supply blood to 
the free wall of the RVOT, were then cannulated and perfused 
with Ca2+-free solution at a rate of 60 ml/min. After about 
15–30 mins of enzymatic solution reperfusion, samples of Epi 
cells (<1.5 mm from the epicardial surface), M cells (2–5 mm 
from the epicardial surface), and Endo cells (<1.5 mm from 
the endocardial surface) were dissected with a fine dermatome 
while carefully avoiding contamination between the three cell 
types. Cell samples were gently agitated, filtered, and washed, 
and then stored at room temperature for later use.
Ito recording
Ito was recorded using whole cell patch-clamp techniques with an 
EPC-9 amplifier, and controlled by Pulse+Pulsefit 8.31 software 
(Heka, Germany) as previously described by our laboratory.24 
Briefly,  cells  were  allowed  to  adhere  to  the  bottom  of  the 
chamber for 3–5 mins, and then were continuously superfused 
with extra cellular solution at a rate of 2 ml/min. Only relaxed 
quiescent  cells  displaying  prominent  cross  striations  were 
used. All experiments were performed at 37°C. The resistance 
of all borosilicate glass pipette tips measured in extracellular 
solution was 2–4 MΩ when filled with pipette solution. After 
whole-cell configuration established, the series resistance and 
the slow capacitance were compensated automatically by Pulse 
8.31  software  to  prevent  large  voltage  errors.  The  activated 
and inactivated voltage-clamp pulse protocols are illustrated in 
Figures 1–5. The peak Ito amplitudes were measured as peak 
amplitudes from baseline minus steady-state values at the end 
of  the  test  pulses.  To  analyze  4-AP-sensitive,  non-calcium 
dependent Ito, it was necessary to minimize other temporarily 
superimposed currents. In our study, the L-type calcium current 
was blocked with 150 µmol/L CdCl2 added to the extracellular 
solution. T-type calcium currents, which are relatively small in 
canine  ventricular  cells,  were  also  reduced  with  extracellular 
CdCl2  solution.  Calcium-activated  chloride  currents  were 
suppressed by blocking ICa with CdCl2, and by using 10 mmol/L 
EGTA in the pipette solution. The fast sodium current was 
inactivated by using a 10-ms prepulse at –45 mV (Figures 1 
and 2).
Drug
Quinidine sulfate (Beijing Municipal Chemical Plant, Beijing, 
China) was dissolved in the external solutions at a concentration 
of 10 mM and diluted to the final concentration.
Statistical analysis
All data were expressed as mean±SEM. and analyzed with SPSS 
11.5.  Differences were  statistically  analyzed  by  the  t  test or 
ANOVA. P<0.05 was considered to be statistically significant. 
Figure s 2, 4, 5 were produced by Graphpad Prism 4.0. Figure 
6 was stimulated by SPSS (Statistical Package for the Social 
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RESulTS
Cell membrane capacitance and activation time
Cell membrane capacitance was similar in canine right ventricular 
RVOT free wall Epi cells (n=19), M cells (n=21), and Endo cells 
(n=17), with values of (156±12) pF, (159±15) pF, and (153±11) 
pF, respectively (between groups, P=NS). Ito in Epi, M, and 
Endo cells was fully activated within (3.8±1.3) ms, (3.3±1.6) 
ms, and (3.4±1.2) ms, respectively (between groups, P=NS), 
and reached steady-state within 100 ms (Figure 1).
Baseline Ito heterogeneity between three cell types 
of the RVOT free wall
At different depolarizing voltage levels, Ito density (pA/pF) 
were the biggest in RVOT free wall Epi cells (n=14), followed 
by M cells (n=14) and, finally, Endo cells (n=12). Ito sometimes 
was absent in Endo cells (Table 1, Figure 1).
At 37°C, using 0.2 Hz depolarization pulses at 0 mV and 
at 70 mV, the average peak Ito density in RVOT Epi cells was 
bigger than that in M cells (7.3±1.3 pA/pF vs. 5.4±1.1 pA/
pF, 31.7±4.1 pA/pF vs. 23.4±3.6 pA/pF, respectively, between 
groups, P<0.05), and far greater than that in Endo cells (7.3±1.3 
pA/pF vs. 1.9±0.16 pA/pF, 31.7±4.1 pA/pF vs. 4.4±1.8 pA/
pF, respectively, between groups, P<0.01). The average peak 
Ito of M cells was significantly greater than that of Endo cells 
(5.4±1.2  pA/pF  vs.  1.9±0.16  pA/pF,  23.4±3.6  pA/pF  vs. 
4.4±1.8  pA/pF,  respectively,  between  groups,  P<0.01).  The 
Figure 1. Typical Ito raw traces of three layer cells from RVOT free 
wall
Figure 2. Ito I-V relationship of three layer cells from RVOT free wall
average peak Ito of Endo cells was far smaller than that of Epi 
and of M cells (Figure 1 and 2).
Baseline Ito Inactivation kinetics 
The time-dependent inactivation course was best fitted with a 
single exponential function yielding similar time constants for 
Epi cells and M cells. The voltage dependence of Ito steady-
state inactivation of Epi cells (n=11) and M cells (n=9) was well 
in accordance with the Boltzmann function, with half points 
(V1/2) of –51.2±2.6 vs. –48.4±2.6 mV (P=NS), respectively, and 
with slope factors of –10.2 ±2.5 mV vs. –9.7±2.3 mV (P=NS), 
respectively.
Voltage Dependent Depression Effect of 10 µM 
quinidine on Ito
Figure 3 and 4 show a typical example of quinidine’s inhibitory 
effect on the same typical RVOT free wall epi cell. As shown 
in Figure 3, the depressive effect onset usually started after 10 
µM quinidine superfusion about 2 mins. It would take about 
7–10 mins the peak depressive effect occurred, after that, the 
peak depressive effect usually lasted about 10–15 mins and it 
was very difficult to reverse the depression effect of quinidine 
after washout. As shown in Figure 4, 10 µM quinidine perfusion 
7–10 mins depressed Ito distinctly at every depolarization levels 
from 10 mV to 70 mV with the voltage dependent pattern. 
At 10mV and 70mV depolarization levels, the Ito depression 
percentage of 10 µM quinidine to RVOT free wall Epi cells were 
41.3%±7% and 63.5%±11%, to M cells were 32.8%±6% and 
58.6%±11%, to Endo cells were 28.2%±9% and 54.5%±13%, 
respectively.Quinidine Depresses the Ito Heterogeneity from RVOT
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Figure 3. A typical example of 10 μM quinidine on the same typical 
Epi cell Ito
Figure 4. I-V relationship of a typical example of 10 μM quinidine on 
the same typical Epi cell Ito
Figure 5. Steady-state inactivation curve of Epi cells before and 
after 10 μM quinidine 5mins
Quinidine  didn’t  alter  the  voltage  dependent  inactivation 
kinetics  course.  Figure  5  shows  the  Boltzmann  Sigmodal 
Equation fitting results for Epi cell (n=9) group before and after 
10µM quinidine (V1/2 –51.2±2.8 mV vs. 56.3±2.5 mV, P=NS; 
Slope Factor –10.2±2.6 mV vs. –9.3±2.5 mV, P=NS). In M cell 
group, the results were consistent with Epi cells group.
Voltage dependent depression effect of 10 µM  
quinidine on RVOT free wall Ito transmural  
electrical heterogeneity
Table 1, 2, and Figure 6 simulated by SPSS 11.5, show the RVOT 
free wall Ito transmural electrical heterogeneity as well as how 
extent 10 µM quinidine could depress this kind of electrical 
heterogeneity. Under baseline condition, the Ito density among 
three layer cells of RVOT free wall displayed a huge transmural 
electrical heterogeneity and Ito voltage gradient. At 0mV, the 
Ito density of Epi cell group (n=14), M cell (n=14) group and 
Endo myocytye (n=12) group were 7.3±1.3 pA/pF, 5.4±1.1 
pA/pF and 1.9±0.16 pA/pF; At 70mV depolarization level, 
the  Ito  density  were  31.7±4.1  pA/pF,  23.4±3.6  pA/pF  and 
4.4±1.8 pA/pF, respectively (Table 1). After 10 µM quinidine 
perfusion  about  5  mins,  the  Ito  density  and  the  transmural 
electrical heterogeneity decreased evidently. At 0 mV, the Ito J Cardiovasc. Dis. Res. Vol 1 / No 1   |  Available Online : www.jcdronline.org  16
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Table 1. Three type cells of RVOT free wall Ito density (pA/pF) at 0 mV and 70 mV depolarization pulses
Cell Types Test Potential (mV)
0 mV 70 mV
Epi Cells (n=14) 7.3±1.3*† 31.7±4.1*†
M Cells (n=14) 5.4±1.1‡ 23.4±3.6‡
Endo Cells (n=12) 1.9±0.16 4.4±1.8
Values are mean±SEM; *P<0.05, Epi Cells vs. M Cells; †P<0.01, Epi Cells vs. Endo Cells; ‡P<0.01, M Cells vs. Endo Cells.
density of Epi cell group (n=8), M cell group (n=7) and Endo 
cell group (n=7) were decreased to 5.5±1.1 pA/pF, 4.1±0.73 
pA/pF and 1.4±0.13 pA/pF; At 70mV depolarization level, the 
Ito density were decreased to 17.4±2.4 pA/pF, 12.9±2.2 pA/
pF and 3.2±1.4 pA/pF, respectively (Table 2). After 7–10 mins 
when the depression effect of 10 µM quinidine reached steady-
state, the Ito density and the transmural electrical heterogeneity 
further decreased. At 0 mV, the Ito density of Epi cell group 
(n=7), M cell group (n=7) and Endo cell group (n=5) were 
decreased to 4.4±0.87 pA/pF, 3.2±0.69 pA/pF and 0.87±0.1 
pA/pF,  respectively;  At  70  mV  depolarization  level,  the  Ito 
density were decreased to 13.3±1.9 pA/pF, 9.8±1.7 pA/pF and 
2.4±1.1 pA/pF, respectively (Table 2).
At baseline condition, 10 µM quinidine perfusion 5 mins and 
7–10 mins, from 0 mV to 70 mV the whole transmural average 
Ito values (which were expressed by green planes in Figure 6A, 
B, C) of RVOT free wall were 10.2 pA/pF, 5.5 pA/pF and 3.5 
pA/pF, respectively (between groups, P<0.01). The inhibitory 
percentage of 10 µM quinidine at 5 mins and 7–10 mins steady-
state level on the the whole Ito transmural heterogeneity of RVOT 
free wall were 46.3%±6% and 66.5%±11%, respectively.
DISCuSSION 
The data above clearly demonstrated that there exists strong 
transmural  Ito  electrical  heterogeneity  in  RVOT  free  wall. 
Quinidine at the concentration of 10 µM, which was in clinical 
therapeutic range, possesses the ability to depress the strong 
transmural  Ito  electrical  heterogeneity  of  RVOT  free  wall 
effectively.
Electrical heterogeneity of three types of  
canine right ventricular cells
Using arterially perfused wedges of canine right ventricle (RV), 
by simultaneously recording transmembrane action potentials 
from 2 epicardial and 1 endocardial sites, together with unipolar 
electrograms and a transmural Electrocardiograph (ECG), Yan 
et al. demonstrated that depression or loss of the action potential 
dome in RV epicardium creates a transmural voltage gradient 
that may be responsible for the ST-segment elevation observed 
in  the  Brugada  syndrome  and  other  syndromes  exhibiting 
similar ECG manifestations. Their results also demonstrated 
that extrasystolic activity due to phase 2 reentry can arise in 
the intact wall of the canine RV and serve as the trigger for 
VT/VF. Their data also pointed to Ito blocker (4-aminopyridine, 
quinidine)  as  an  effective  pharmacological  treatment.12 
However, for the RVOT free wall, which was regarded as the 
seedbeds of Brugada syndrome and some IVF, the information 
on trnasmural electrical heterogeneity, especially Ito trnasmural 
electrical heterogeneity of RVOT free wall was very limited. Our 
data above clearly indicated that there exist marked Ito electrical 
heterogeneity  and  transmural  wall  voltage  gradients  between 
Epi cells and Endo cells, and between M cells and Endo cells in 
the canine RVOT free wall. So, our results not only confirm the 
existence of potent Ito electrical heterogeneity in the RVOT free 
wall, but also provide further convincing quantitative evidence 
supporting the hypothesized mechanism for J wave formation, 
J point elevation, and ST-segment elevation on ECG of right 
precordial leads.
Clinical relevance
The electrical heterogeneity of the right ventricle has a close 
relationship with certain right ventricular malignant arrhythmias 
found in patients with Brugada syndrome and some IVFs.
Recently,  more  and  more  studies  have  verified  in  most 
rodents, canines, and humans, there is obvious Ito electrical 
heterogeneity  in  the  ventricles  during  repolarization  (phase 
1).  The  different  Ito  distributions  and  transmural  voltage 
gradients are among the most prominent and most important 
manifestations of right ventricular electrical heterogeneity, and 
one of the important ionic bases for the “spike and dome” 
action  potential  differences  between  the  three  cell  types, 
Table 2. After perfusion 5mins and 7–10mins, the voltage dependent inhibItory effect of 10 μM quinidine on RVOT 
free wall Ito (pA/pF)
Cell Types 0mV 70mV
Baseline 5mins 7–10mins Baseline 5mins 7–10mins
Epi Cells 7.3±1.3 5.5±1.1* 4.4±0.87** 31.7±4.1 17.4±2.4† 13.3±1.9††
M Cells 5.4±1.1 4.1±0.73‡ 3.2±0.69‡‡ 23.4±3.6 12.9±2.2§ 9.8±1.7§§
Endo Cells 1.9±0.16 1.4±0.13¶ 0.87±0.1¶¶ 4.4±1.8 3.2±1.4# 2.4±1.1##
Values are mean±SEM; *P<0.05, 10 μM quinidine 5 mins vs. Baseline; †P<0.01, quinidine 5 mins vs. Baseline; ‡P<0.05, 10 μM quinidine 
5 mins vs. Baseline; §P<0.01, quinidine 5 mins vs. Baseline; #P<0.01, quinidine 5 mins vs. Baseline; ¶P<0.05, 10 μM quinidine 5 mins vs. 
Baseline; **P<0.01, quinidine 7–10 mins vs. Baseline; ††P<0.01, quinidine 7–10 mins vs. Baseline. ‡‡P<0.01, quinidine 7–10 mins vs. Baseline; 
§§P<0.01, quinidine 7–10 mins vs. Baseline. ¶¶P<0.01, quinidine 7–10 mins vs. Baseline; ## P<0.01, quinidine 7–10 mins vs. Baseline.Quinidine Depresses the Ito Heterogeneity from RVOT
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1), may be one of the main electrophysiological mechanisms 
for sudden cardiac death in patients with Brugada syndrome 
and  other  conditions,3–8,10,12  although,  there  are  still  some 
controversies.26
Under the supporting of the electrical heterogeneity and 
the  repolarization  disorder  theory  above,  recently  quinidine, 
as an adjunct to ICD therapy, has been used in treatment of 
IVF, Brugada syndrome and short QT syndrome successfully. 
More and more papers reported the profit of antiarrhythmic 
therapy with quinidine as an adjunct to ICD therapy to abort 
electrical storms, or the profit of quinidine as an alternative 
to device therapy when use of an ICD is not possible.14, 15, 
17–23 However, limited information can be available on the Ito 
transmural  electrical  heterogeneity  of  RVOT  free  wall,  one 
important seedbed for some clinical malignant arrhythmia and 
much less is known how extent quinidine in clinical therapeutic 
concentration range can depress the Ito transmural electrical 
heterogeneity coming from RVOT free wall. So, our results 
primarily answered the critical problems above and provided 
a further evidence for quinidine in treatment of some IVF, 
Brugada syndrome and short QT syndrome.
Based on the results of our study, we can conclude that there 
exists a robust Ito transmural electrical heterogeneity in RVOT 
free wall and quinidine in clinical therapeutic concentration can 
depress this kind of heterogeneity effectively.
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Figure 6A. Baseline RVOT Free Wall Ito Transmural Electrical 
Heterogeneity 3-Dimension Figure Simulated by SPSS 11.5: X axis 
stands for test potential; Y axis stands for Ito density; Z axis stands 
for three layer cells; The height of pink cones stands for Ito density 
of each cell types at different test potential; The green plane stands 
for the whole transmural average Ito values of RVOT free wall; The 
yellow bent smooth plane stands for the whole transmural Ito gradi-
ent of RVOT free wall.
Figure 6B. After 10 μM quinidine perfusion 5mins
and for J point elevation, J wave formation and ST-segment 
elevation,  action  potential  asymmetrical  loss,  “all  or  none” 
repolarization, and reentry into phase 2. VT or VF induced by 
phase 2 reentries, as a result of powerful transmural Ito electrical 
heterogeneity in the right ventricle during repolarization (phase 
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ABBREVIATIONS
Sudden Cardiac Death (SCD), Catecholaminergic Polymorphic 
Ventricular  Tachycardia  (CPVT),  Idiopathic  Ventricular 
Fibrillation (IVF), Right Ventricular Outflow Tract (RVOT), 
Transient  Outward  Potassium  Current  (Ito),  Epicardial 
(Epi),  Midmyocardial  (M),  Endocardial  (Endo),  Ventricular 
Tachycardia  (VT),  Ventricular  Fibrillation  (VF),  Implantable 
Cardioverter Defibrillator (ICD).
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